Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002504-41
    Sponsor's Protocol Code Number:B7461027
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2020-10-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-002504-41
    A.3Full title of the trial
    Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase
    Inhibitor (TKI)
    Studio a braccio singolo di lorlatinib in partecipanti affetti da carcinoma polmonare non a piccole cellule (NSCLC) positivo per la chinasi del linfoma anaplastico (ALK) con progressione della malattia dopo un precedente inibitore tirosinchinasico (TKI) ALK di seconda generazione
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of Lorlatinib In Participants with Anaplastic Lymphoma Kinase (ALK)-Positive NSCLC
    Studio di lorlatinib in partecipanti con NSCLC positivo per la chinasi del linfoma anaplastico (ALK)
    A.3.2Name or abbreviated title of the trial where available
    -
    -
    A.4.1Sponsor's protocol code numberB7461027
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPFIZER INC
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPfizer Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPfizer Inc.
    B.5.2Functional name of contact pointClinical Trials.gov Call Centre
    B.5.3 Address:
    B.5.3.1Street Address235 East 42nd Street
    B.5.3.2Town/ cityNew York
    B.5.3.3Post codeNY 10017
    B.5.3.4CountryUnited States
    B.5.4Telephone number+18007181021
    B.5.6E-mailClinicalTrials.gov_Inquiries@pfizer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLorlatinib
    D.3.2Product code [PF-06463922]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLorlatinib
    D.3.9.1CAS number 1454846-35-5
    D.3.9.2Current sponsor codePF-06463922
    D.3.9.4EV Substance CodeSUB181272
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    ALK-positive metastatic non-small-cell lung cancer
    Carcinoma polmonare non a piccole cellule metastatico ALK-positivo
    E.1.1.1Medical condition in easily understood language
    Lung cancer
    Carcinoma polomare
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10061873
    E.1.2Term Non-small cell lung cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess Overall and Intracranial Response Rate of single-agent lorlatinib in participants with advanced ALK positive NSCLC whose disease has progressed on alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy
    Valutare il tasso di risposta complessiva e intracranica di lorlatinib come singolo agente nei partecipanti con carcinoma polmonare non a piccole cellule (Non-Small Cell Lung Cancer, [NSCLC]) in stadio avanzato positivo per la chinasi del linfoma anaplastico (Anaplastic Lymphoma Kinase, [ALK]), la cui malattia sia progredita durante una terapia con alectinib o ceritinib come terapia di prima linea con un inibitore tirosinchinasico (Tyrosine Kinase Inhibitor, [TKI]) di ALK
    E.2.2Secondary objectives of the trial
    1 To assess secondary measures of clinical efficacy
    2 To confirm the safety and tolerability of lorlatinib
    1 Valutare le misure secondarie di efficacia clinica
    2 Confermare la sicurezza e la tollerabilità di lorlatinib
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Participants are eligible to be included in the study only if all of the following criteria apply:
    1. Participant must be >= 18 years of age inclusive (or >= 20 years of age if required by local regulation), at the time of signing the informed consent.
    2. Participants must have evidence of histologically or cytologically confirmed diagnosis of metastatic NSCLC (Stage IV, American Joint Committee on Cancer [AJCC] v7.0) that carries an ALK rearrangement, as determined by FDA approved fluorescence in situ hybridization assay or by Immunohistochemistry.
    3. disease progression after alectinib or ceritinib as first line therapy.
    Participants may have had prior chemotherapy, but only if before starting treatment with alectinib or ceritinib. All Participants must have at least one measurable target extracranial lesion according to RECIST v1.1. Participants with asymptomatic CNS metastases will be eligible.
    The brain metastases may be newly diagnosed or be present as progressive disease after surgery, whole brain radiotherapy or stereotactic radiosurgery. 4.Participants who have leptomeningeal disease or carcinomatous meningitis will be eligible if the LM/CM is visualized on magnetic resonance imaging or if documented baseline cerebral spinal fluid positive cytology is available.
    5. Eastern Cooperative Oncology Group Performance Status 0 or 1.
    6. Adequate bone marrow functioning.
    7. Adequate pancreatic function.
    8. Adequate renal function.
    9. Adequate liver function.
    10. Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade =<1 except for adverse events (AEs) that in the investigator'
    judgment do not constitute a safety risk for the participant.
    11. Systemic anti-cancer therapy with alectinib or ceritinib discontinued within a minimum of 5 half-lives prior to first dose of lorlatinib on the study.
    12. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
    I partecipanti possono essere inclusi nello studio solo se si applicano tutti i seguenti criteri:
    1. Il partecipante deve avere> = 18 anni inclusi (o> = 20 anni se richiesto dalla normativa locale), al momento della firma del consenso informato.
    2. I partecipanti devono essere in possesso di prove di diagnosi istologicamente o citologicamente confermate di NSCLC metastatico (Stadio IV, American Joint Committee on Cancer [AJCC] v7.0) che trasporta un riarrangiamento ALK, come determinato dal test di ibridazione in situ con fluorescenza approvato dalla FDA o da Immunohistochemistry .
    3. progressione della malattia dopo alectinib o ceritinib come terapia di prima linea.
    I partecipanti possono aver avuto la chemioterapia precedente, ma solo se prima di iniziare il trattamento con alectinib o ceritinib. Tutti i partecipanti devono avere almeno una lesione extracranica bersaglio misurabile secondo RECIST v1.1. Saranno ammessi i partecipanti con metastasi asintomatiche del SNC.
    Le metastasi cerebrali possono essere di nuova diagnosi o essere presenti come malattia progressiva dopo un intervento chirurgico, radioterapia cerebrale intera o radiochirurgia stereotassica.
    4. I partecipanti che hanno una malattia leptomeningea o una meningite carcinomatosa saranno idonei se il LM / CM è visualizzato su risonanza magnetica o se è disponibile una citologia positiva al fluido spinale cerebrale documentata.
    5. Eastern Cooperative Oncology Group Performance Status 0 o 1.
    6. Adeguato funzionamento del midollo osseo.
    7. Adeguata funzione pancreatica.
    8. Adeguata funzione renale.
    9. Adeguata funzione epatica.
    10. Gli effetti acuti di qualsiasi terapia precedente sono stati risolti in gravità basale o in CTCAE Grado = <1, tranne per gli eventi avversi che a giudizio dello Sperimentatore non costituiscono un rischio per la sicurezza del parecipante.
    11. La terapia anticancro sistemica con alectinib o ceritinib è stata interrotta entro un minimo di 5 emivite prima della prima dose di lorlatinib nello studio.
    12. L'uso contraccettivo da parte di uomini o donne deve essere coerente con le normative locali relative ai metodi contraccettivi per coloro che partecipano agli studi clinici. Lo Sperimentatore è responsabile della revisione della storia medica, della storia mestruale e della recente attività sessuale per ridurre il rischio di inclusione di una donna con una gravidanza precoce non rilevata.
    E.4Principal exclusion criteria
    Medical Conditions
    1. Prior ALK TKI treatment or anti-cancer treatment other than first line alectinib or ceritinib.
    2. Spinal cord compression.
    3. Gastrointestinal abnormalities.
    4. Active and clinically significant bacterial, fungal, or viral infection.
    5. Clinically significant vascular and non-vascular cardiac conditions.
    6. Participants presenting with abnormal Left Ventricular Ejection Fraction by echocardiogram or Multi-Gated Acquisition Scan according to institutional lower limits.
    7. Participants with predisposing characteristics for acute pancreatitis according to investigator judgment.
    8. History or known presence of interstitial fibrosis, interstitial lung disease, pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis.
    9. Other severe acute or chronic medical or psychiatric condition
    10. Evidence of active malignancy.
    11. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (10 fractions) must have been completed at least 48 hours prior to study entry. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry. Whole brain radiation must have completed at least 4 weeks
    prior to study entry.
    12. Prior irradiation to >25% of the bone marrow.
    13. Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of lorlatinib: a. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort).
    b. Known strong CYP3A inhibitors (eg, strong CYP3A4 inhibitors:grapefruit juice or grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos], boceprevir, cobicistat, clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, paritaprevir and posaconazole, ritonavir, alone and with danoprevir or elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir,
    telaprevir, troleandomycin, and voriconazole, grapefruit juice or grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos]). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed. Note that strong CYP3A inhibitors can be stopped up to one day prior to first dose of lorlatinib on study.
    c.Known CYP3A substrates with narrow therapeutic index, such as astemizole*, terfenadine*, cisapride*, pimozide, quinidine, tacrolimus,
    cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) (*withdrawn from United States [US] market).
    Known permeability glycoprotein (P-gp) substrates with a narrow therapeutic index (eg, digoxin).
    14. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.
    Condizioni mediche
    1. Precedente trattamento con ALK TKI o trattamento anticancro diverso da alectinib di prima linea o ceritinib.
    2. Compressione del midollo spinale.
    3. Anomalie gastrointestinali.
    4. Infezione batterica, fungina o virale attiva e clinicamente significativa.
    5. Condizioni cardiache vascolari e non vascolari clinicamente significative.
    6. Partecipanti che presentano anomala frazione di eiezione ventricolare sinistra mediante ecocardiogramma o scansione di acquisizione multi-gate secondo limiti inferiori istituzionali.
    7. Partecipanti con caratteristiche predisponenti per pancreatite acuta secondo il giudizio dello sperimentatore.
    8. Storia o presenza nota di fibrosi interstiziale, malattia polmonare interstiziale, polmonite, polmonite da ipersensibilità, polmonite interstiziale, bronchiolite obliterante e fibrosi polmonare.
    9. Altre condizioni mediche o psichiatriche acute o croniche gravi.
    10. Evidenza di malignità attiva.
    11. Radioterapia (eccetto palliativo per alleviare il dolore osseo) entro 2 settimane dall'ingresso nello studio. Le radiazioni palliative (10 frazioni) devono essere state completate almeno 48 ore prima dell'ingresso nello studio. L'irradiazione cerebrale stereotassica o di piccolo campo deve essere stata completata almeno 2 settimane prima dell'ingresso nello studio. Le radiazioni del cervello intero devono essere state completate per almeno 4 settimane prima dell'ingresso nello studio.
    12. Prima irradiazione a> 25% del midollo osseo.
    13. Uso concomitante di uno dei seguenti alimenti o farmaci (consultare lo sponsor in caso di dubbio se un alimento o un farmaco rientri in una delle categorie sopra indicate) entro 12 giorni prima della prima dose di lorlatinib:
    a. Induttori potenti noti del CYP3A (ad es. Carbamazepina, enzalutamide, mitotano, fenitoina, rifampicina, erba di San Giovanni).
    b. Inibitori potenti noti del CYP3A (p. Es., Potenti inibitori del CYP3A4: succo di pompelmo o pompelmo / agrumi correlati al pompelmo [p. Es., Arance di Siviglia, pomelos], boceprevir, cobicistat, claritromicina, conivaptan,
    diltiazem, idelalisib, indinavir, itraconazolo, ketoconazolo, lopinavir, nefazodone, nelfinavir, paritaprevir and posaconazolo, ritonavir, da soli e con danoprevir or elvitegravir or indinavir or lopinavir or
    paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir, troleandomicina, e voriconazolo, succo di pompelmo o agrumi a base di pompelmo / pompelmo [ad esempio, arance di Siviglia, pomeli]). È consentito l'uso topico di questi farmaci (se applicabile), come la crema al 2% di ketoconazolo. Si noti che forti inibitori del CYP3A possono essere sospesi fino a un giorno prima della prima dose di lorlatinib durante lo studio.
    c. substrati noti del CYP3A con indice terapeutico ristretto, come astemizolo *, terfenadina *, cisapride *, pimozide, chinidina, tacrolimus, ciclosporina, sirolimus, alfentanil, fentanil (compreso cerotto transdermico) o alcaloidi ergot (ergotamina, diidroergotamina) (* ritirati dal mercato degli Stati Uniti [USA]).
    Substrati di glicoproteina (P-gp) noti a permeabilità con un indice terapeutico ristretto (ad es. Digossina).
    14. Chirurgia maggiore entro 4 settimane prima dell'arruolamento. Non sono esclusi interventi chirurgici minori, ma deve essere trascorso un tempo sufficiente per un'adeguata guarigione della ferita.
    E.5 End points
    E.5.1Primary end point(s)
    Confirmed Objective Tumor Response assessed by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 per ICR
    Risposta obiettiva del tumore confermata, valutata mediante i Criteri di valutazione della risposta nei tumori solidi (Response Evaluation Criteria In Solid Tumors, [RECIST]) versione 1.1 mediante Revisione centrale indipendente (Independent Central Review, [ICR])
    E.5.1.1Timepoint(s) of evaluation of this end point
    During the whole study
    Durante tutto lo studio
    E.5.2Secondary end point(s)
    1. Every endpoint assessed by RECIST version 1.1
    2. Confirmed ObjectiveTumor Response assessed by INV
    3. Confirmed Intracranial tumor response assessed per ICR and INV
    4. TTR per ICR and INV
    5. DOR per ICR and INV
    6. Duration of Intracranial response (IC-DOR) per ICR and INV
    7. TTP per ICR and INV
    8. PFS per ICR and INV
    9. Adverse Events as characterized by type, frequency, severity (as
    graded by National Cancer Institute Common Terminology Criteria for
    Adverse Events [NCI CTCAE] v.4.03), seriousness, and relationship to
    1. Ogni endpoint è valutato secondo i criteri RECIST versione 1.1
    2. Risposta tumorale obiettiva confermata, valutata dallo sperimentatore
    3. Risposta tumorale intracranica confermata, valutata mediante ICR e dallo sperimentatore
    4. Tempo nell’intervallo terapeutico (Time in Therapeutic Range, [TTR]) secondo l’ICR e lo sperimentatore
    5. Durata della risposta (Durantion of Response, [DOR]) secondo l’ICR e lo sperimentatore
    6. Durata della risposta intracranica (IC-DOR) secondo l’ICR e lo sperimentatore
    7. Tempo alla progressione del tumore (Time to Tumor Progression, [TTP]) secondo l’ICR e lo sperimentatore
    8. Sopravvivenza libera da progressione (Progression-Free Survival, [PFS]) secondo l’ICR e lo sperimentatore
    9. Eventi avversi caratterizzati per tipo, frequenza, gravità (valutata in base ai Criteri terminologici comuni per gli eventi avversi [Common Terminology Criteria for Adverse Events, [CTCAE] del National Cancer Institute [NCI] v.4.03), serietà e relazione con la terapia dello studio
    E.5.2.1Timepoint(s) of evaluation of this end point
    During the whole study
    Durante tutto lo studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA25
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Italy
    Poland
    Spain
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The End of Trial is defined as 12 calendar months after the “last patient first visit” (LPFV) date in the study.
    La fine dello studio è definita come 12 mesi di calendario dopo la data dell'ultima visita del paziente (LPFV) in studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 45
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 25
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 53
    F.4.2.2In the whole clinical trial 70
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the End of Trial a number of options for ensuring continued supply with lorlatinib will be considered based on the local availability of the treatment and local country laws/regulation.
    Alla fine della sperimentazione, saranno prese in considerazione diverse opzioni per garantire una fornitura continua di lorlatinib in base alla disponibilità locale del trattamento e alle leggi/normative nazionali locali.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-07-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-05-19
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 00:21:55 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA